Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-19
2011-04-19
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07928082
ABSTRACT:
Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
REFERENCES:
patent: 5646042 (1997-07-01), Stinchcomb et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 5998148 (1999-12-01), Bennet et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: 6310047 (2001-10-01), Farrell et al.
patent: 7297684 (2007-11-01), Gleave et al.
patent: 2003/0087857 (2003-05-01), Freier
patent: WO 00/69454 (2000-11-01), None
patent: 00/78341 (2000-12-01), None
patent: WO 00/78341 (2000-12-01), None
patent: 01/05435 (2001-01-01), None
patent: WO 01/05435 (2001-01-01), None
patent: 02/22642 (2002-03-01), None
Miyake et al (Int. J. Urology 8: 337-349, 2001).
Huynh et al (Cell Growth Diff. 7: 1501-1506, 1996).
Rozen et al (J. Nat. Canc. Inst 89: 652-656, 1997).
Butt et al (J. Biol. Chem. 278(32): 29676-29685, 2003).
Beattie et al (Biochem. J. 395: 1-19, 2006).
Hung et al (J. Pathol. 214: 368-376, 2008).
Akkiprik (Breast Cancer Res. 10:212, 2008).
Wang et al (Neuroendocrinol. 66: 203-211, 1997).
Miyake et al (Canc. Res. 60: 3058-3064, 2000).
Giannini (J. Clin. Endocrinol. Metab. 79(6): 1824-1830, 1994).
Verrecchia et al (J. Invest. Dermatol. 116: 755-763, 2001).
Kretschmer-Kazemi Far et al (Bioinformatics 17(11): 1058-1061, 2001).
Patzel (Nucl. Acids Res. 27(22): 4328-4334, 1999.
Zangemeister et al. (Clinical Cancer Research 6: 2547-2555, 2005.
Agrawal et al., “Antisense Therapeutics: Is it as simple as complementary base recognition”, Molecular Medicine Today, 2000, pp. 72-81, vol. 6, Publisher: Elsevier Science Ltd.
Andress et al., “Human Osteoblast-derived Insulin-like Growth Factor (IGF) Binding Protein-5 Stimulates Osteoblast Mitogenesis and Potentiates IGF Action”, The Journal of Biological Chemistry, Nov. 1992, vol. 267, No. 31, pp. 22467-22472.
Angelloz-Nicoud et al., Autocrine Regulation of Cell Proliferation by the Insulin-Like Growth Factor (IGF) and IGF Binding Protein-3 Protease System in a Human Prostate Carcinoma Cell Line (PC-3), Endocrinology, 1995, vol. 136, No. 12, pp. 5485-5492.
Boudon et al., “Secretion of Insulin-Like Growth Factors and Their Binding Proteins by Human Normal and Hyerplastic Prostatic Cells in Primary Culture”, Journal of Clinical Endocrinology and Metabolism, vol. 81, No. 2, pp. 612-617, Feb. 1, 1996.
Branch, Andrea D., “A good antisense molecule is hard to find”, TIBS, 1998, pp. 45-50, Publisher: Elsevier Science Ltd.
Crooke et al., “Basic Principles of Antisense Therapeutics, Antisense Research and Application”, 2004, pp. 1-50, Publisher: Springer.
Cucco, et al., “In Vitro and in Vivo Reversal of Multidrug Resistance in a Human Leukemia-resistant Cell Line by mdr1 Antisense Oligodeoxynucleotides1”, Cancer Research, Oct. 1, 1996, vol. 56, pp. 4332-4337.
Damon et al., “Overexpression of an Inhibitory Insulin-Like Growth Factor Binding Protein (IGFBP), IGFBP-4, Delays Onset of Prostate?Tumor Formation”, Endocrinology, 1998, vol. 139, No. 8, pp. 3456-3464.
Elgin et al., “An insulin-like growth factor (IGF) binding protein enhances the biologic response to IG-1,”, Proc. Natl. Acad. Sci. USA, May 1987, vol. 84, pp. 3254-3258.
Figueroa et al., “Differential Expression of Insulin-Like Growth Factor Binding Proteins in High Versus Low Gleason Score Prostate Cancer”, The Journal of Urology, Apr. 1998, vol. 159(4), pp. 1379-1383.
Huynh et al., “Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells”, The Journal of Biological Chemistry, Jan. 1996, vol. 271, No. 2, pp. 1016-1021.
Jansen et al., “bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice”, Nature Medicine, Feb. 1998, vol. 4, No. 2, pp. 232-234.
Jen et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies”, Stem Cells 2000, 2000, pp. 307-319, vol. 18.
Monia et al., “Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase”, Nature Medicine, Jun. 1996, vol. 2, No. 6 pp. 668-675.
Nickerson et al., “Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,5, and 5”, Endocrinology, 1998, vol. 139, No. 2, pp. 807-810.
Oh et al., “Management of Hormone Refractory Prostate Cancer: Current Standards and Future Prospects”, The Journal of Urology, Oct. 1998, vol. 160(4), pp. 1220-1229.
Oh et al., “Insulin-like Growth Factor (IGF)-independent Action of IGF-binding Protein-3 in Hs578T Human Breast Cancer Cells”, The Journal of Biological Chemistry, 1993, vol. 268, No. 20, pp. 14964-14971.
Opalinska et al., “Nucleic-acid therapeutics: Basic principles and recent applications”, Nature Reviews, 2002, pp. 503-514, vol. 1.
Rajaram et al., “Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions”, Endocrine Reviews, 1997, vol. 18(6), pp. 801-831.
Ziegler et al., “Induction of Apoptosis in Small-Cell Lung Cancer Cells by an Antisense Oligodeoxynucleotide Targeting the Bcl-2 Coding Sequence”, Journal of the National Cancer Institute, Jul. 16, 1997, vol. 89, No. 14, pp. 1027-1036.
Gleave Martin E.
Signaevsky Maxim
Larson & Anderson LLC
Schnizer Richard
The University of British Columbia
LandOfFree
Bispecific antisense oligonucleotides that inhibit IGFBP-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific antisense oligonucleotides that inhibit IGFBP-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific antisense oligonucleotides that inhibit IGFBP-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689173